Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.

Détails

ID Serval
serval:BIB_E88187EC061E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Périodique
Transplant infectious disease
Auteur⸱e⸱s
Hofmann E., Sidler D., Dahdal S., Bittel P., Suter-Riniker F., Manuel O., Walti L.N., Hirzel C.
ISSN
1399-3062 (Electronic)
ISSN-L
1398-2273
Statut éditorial
Publié
Date de publication
06/2021
Peer-reviewed
Oui
Volume
23
Numéro
3
Pages
e13515
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Ganciclovir (GCV)-resistant cytomegalovirus (CMV) infection is a common problem among solid organ transplant (SOT) recipients without prior CMV immunity (CMV D+/R-). GCV-resistant CMV represents a particular challenge for CMV management. Letermovir is a recently licensed antiviral agent for primary CMV prophylaxis in allogenic hematopoietic stem cell transplant (HSCT) recipients. Given the favorable safety profile and its oral bioavailability letermovir may be considered a valuable off-label option for secondary prophylaxis of GCV-resistant CMV in SOT recipients. Here, we describe our experience with letermovir as secondary prophylaxis for GCV-resistant CMV in two renal transplant recipients and review the literature in regard of previously published cases. Letermovir resistance emerged after a few months of secondary prophylaxis in the two renal transplant recipients. In both cases, the previously described UL56 C325Y letermovir resistance mutation was detected. In vitro studies of letermovir suggest a relatively low genetic barrier to resistance. Therefore, caution is warranted when using letermovir as secondary prophylaxis for GCV-resistant CMV infection.
Mots-clé
Acetates, Antiviral Agents/therapeutic use, Cytomegalovirus, Cytomegalovirus Infections/drug therapy, Drug Resistance, Viral, Ganciclovir/therapeutic use, Humans, Organ Transplantation, Quinazolines, Transplant Recipients, human cytomegalovirus infection (CMV), letermovir resistance, secondary CMV prophylaxis, solid organ transplant
Pubmed
Web of science
Création de la notice
28/11/2020 11:03
Dernière modification de la notice
02/02/2023 7:52
Données d'usage